📊 ABEO Key Takeaways
Is Abeona Therapeutics Inc.. (ABEO) a Good Investment?
Abeona Therapeutics exhibits severe operational distress with massive operating losses (-$89.4M) and negative free cash flow (-$84.3M) that cannot be sustained despite positive net income driven by non-cash items. The company's profitability metrics are distorted by one-time gains, while underlying cash generation remains deeply negative, indicating fundamental business model challenges in pharmaceutical development.
Abeona Therapeutics shows strong balance-sheet liquidity and low leverage, which provides meaningful funding flexibility for a development-stage biotech. However, core fundamentals remain weak: revenue is still very small, operating losses are severe, and free cash flow is deeply negative, while the sharp swing to net income appears low quality relative to the underlying cash burn and operating performance. The company’s fundamental case depends more on improving commercialization and narrowing operating losses than on its current reported earnings.
Why Buy Abeona Therapeutics Inc.. Stock? ABEO Key Strengths
- Strong liquidity position with $78.4M cash and 6.93x current ratio provides runway for operations
- Low leverage with 0.13x debt-to-equity ratio limits financial distress risk
- Revenue growth of 66.3% YoY shows commercialization progress in pharmaceutical pipeline
- Very strong liquidity, with $78.44M in cash and a 6.93x current ratio
- Low financial leverage, with debt/equity of 0.13x and modest long-term debt relative to equity
- Revenue grew 66.3% year over year, indicating early top-line momentum
ABEO Stock Risks: Abeona Therapeutics Inc.. Investment Risks
- Operating losses of -$89.4M with -1536.9% operating margin indicate core business is unprofitable and not scalable
- Negative free cash flow of -$84.3M with current cash burn rate exhausts $78.4M in roughly 10 months without additional financing
- Positive net income of $71.2M contradicts negative operating cash flow, suggesting earnings quality issues driven by non-cash gains or one-time items rather than sustainable operations
- High insider form 4 filing activity (23 in 90 days) may indicate insider concern or active restructuring
- Operating margin of -1536.9% shows the business is far from self-sustaining
- Operating cash flow of -$76.33M and free cash flow of -$84.30M indicate heavy ongoing cash burn
- Net income quality is questionable because reported profitability is not supported by operating income or cash generation
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Revenue growth sustainability and gross margin expansion as pipeline matures
- Cash runway and timeline to profitability or next financing requirement
- Quarterly revenue growth and whether product revenue becomes more meaningful
- Operating cash burn and the pace of improvement in operating loss/free cash flow
Abeona Therapeutics Inc.. (ABEO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.93x current ratio provides a solid financial cushion.
ABEO Profit Margin, ROE & Profitability Analysis
ABEO vs Healthcare Sector: How Abeona Therapeutics Inc.. Compares
How Abeona Therapeutics Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Abeona Therapeutics Inc.. Stock Overvalued? ABEO Valuation Analysis 2026
Based on fundamental analysis, Abeona Therapeutics Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Abeona Therapeutics Inc.. Balance Sheet: ABEO Debt, Cash & Liquidity
ABEO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Abeona Therapeutics Inc..'s revenue has declined by 42% over the 5-year period, indicating business contraction. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
ABEO Revenue Growth, EPS Growth & YoY Performance
ABEO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $400.0K | -$5.2M | $-0.10 |
| Q2 2025 | $400.0K | $7.4M | $-0.26 |
| Q3 2024 | $3.5M | -$11.8M | $-0.48 |
| Q2 2024 | $3.5M | $7.4M | $-0.26 |
| Q3 2023 | $1.3M | -$6.4M | $-0.48 |
| Q2 2023 | $1.0M | -$4.1M | $0.92 |
| Q1 2023 | $346.0K | -$9.1M | N/A |
| Q3 2022 | $1.3M | -$7.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Abeona Therapeutics Inc.. Dividends, Buybacks & Capital Allocation
ABEO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Abeona Therapeutics Inc.. (CIK: 0000318306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABEO
What is the AI rating for ABEO?
Abeona Therapeutics Inc.. (ABEO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABEO's key strengths?
Claude: Strong liquidity position with $78.4M cash and 6.93x current ratio provides runway for operations. Low leverage with 0.13x debt-to-equity ratio limits financial distress risk. ChatGPT: Very strong liquidity, with $78.44M in cash and a 6.93x current ratio. Low financial leverage, with debt/equity of 0.13x and modest long-term debt relative to equity.
What are the risks of investing in ABEO?
Claude: Operating losses of -$89.4M with -1536.9% operating margin indicate core business is unprofitable and not scalable. Negative free cash flow of -$84.3M with current cash burn rate exhausts $78.4M in roughly 10 months without additional financing. ChatGPT: Operating margin of -1536.9% shows the business is far from self-sustaining. Operating cash flow of -$76.33M and free cash flow of -$84.30M indicate heavy ongoing cash burn.
What is ABEO's revenue and growth?
Abeona Therapeutics Inc.. reported revenue of $5.8M.
Does ABEO pay dividends?
Abeona Therapeutics Inc.. does not currently pay dividends.
Where can I find ABEO SEC filings?
Official SEC filings for Abeona Therapeutics Inc.. (CIK: 0000318306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABEO's EPS?
Abeona Therapeutics Inc.. has a diluted EPS of $1.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABEO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Abeona Therapeutics Inc.. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ABEO stock overvalued or undervalued?
Valuation metrics for ABEO: ROE of 44.7% (sector avg: 15%), net margin of 1,223.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ABEO stock in 2026?
Our dual AI analysis gives Abeona Therapeutics Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ABEO's free cash flow?
Abeona Therapeutics Inc..'s operating cash flow is $-76.3M, with capital expenditures of $8.0M. FCF margin is -1,448.5%.
How does ABEO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,223.1% (avg: 12%), ROE 44.7% (avg: 15%), current ratio 6.93 (avg: 2).
Why is ABEO's return on equity (ROE) so high?
Abeona Therapeutics Inc.. has a return on equity of 44.7%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 1,223.1% net margin.